GlassScriptPhysician profile
Chelsea Roe
NPI 1649899071
$3,765.40
in general payments reported to CMS, 2019-2025
48 companies · $120 in 2025
The $120 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,285 · 2022: $1,098 · 2023: $838 · 2024: $426 · 2025: $120.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,229 · Education: $154.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,229.24 |
| Education | $153.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $326.77 | 2021-2023 | Erleada |
| Pharmacyclics LLC, An Abbvie Company | $295.04 | 2021-2023 | Imbruvica, Epkinly |
| Merck Sharp & Dohme LLC | $254.03 | 2021-2023 | Keytruda, Lynparza |
| Seagen INC. | $234.69 | 2021-2023 | Adcetris |
| Astrazeneca Pharmaceuticals LP | $223.65 | 2021-2024 | Imfinzi |
| Novartis Pharmaceuticals Corporation | $209.90 | 2021-2024 | |
| Pfizer INC. | $201.03 | 2021-2024 | |
| Amgen INC. | $162.59 | 2021-2023 | Blincyto, Kyprolis |
| Takeda Pharmaceuticals U.S.A., INC. | $126.60 | 2021 | |
| Genzyme Corporation | $110.27 | 2022-2024 | |
| Abbvie INC. | $101.81 | 2025 | |
| Astellas Pharma US INC | $93.23 | 2021-2022 | |
| Incyte Corporation | $83.37 | 2021-2023 | Jakafi |
| Beigene USA, INC. | $82.91 | 2023-2024 | Brukinsa |
| Glaxosmithkline, LLC. | $76.87 | 2021-2023 | Zejula, Jemperli |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chelsea Roe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.